Machine learning is reshaping the way portfolios are built, monitored, and adjusted. Investors are no longer limited to ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback